SSY GROUP (02005): Bumetanide has been approved by the National Medical Products Administration and registered as an active pharmaceutical ingredient for use in marketed preparations.

SSY GROUP (02005) announced that its bumetanide has been approved by the China National Medical Products Administration (NMPA) for registration as an active pharmaceutical ingredient in marketed formulations. Bumetanide is a loop diuretic primarily used to treat edema associated with heart failure and renal or hepatic impairment. It is also used to prevent acute renal failure and to treat hypertension, hyperkalemia, hypercalcemia, dilutional hyponatremia, syndrome of inappropriate antidiuretic hormone secretion (SIADH), and acute drug toxicity.